Methods and immunogenic compositions relating to HER2 with selective sequence modifications
Only limited success has been previously achieved from cancer vaccines targeting unmodified tumor-associated self-antigens and new compositions and methods are needed. Immunogenic compositions and methods of use thereof are provided according to the present disclosure which include a protein effective to stimulate immune activity against a tumor-associated self-antigen, or a variant thereof which is a tumor-associated self-antigen.
1 . A method of stimulating immune activity against a tumor-associated self-antigen, HER2, in a subject, comprising:
administering a therapeutically effective amount of an immunogenic composition comprising: a protein, the protein consisting of: amino acid sequence SEO ID NO:2 to the subject.
2 . The method of claim 1 , wherein the immunogenic composition further comprises a pharmaceutically acceptable carrier.
3 . The method of claim 1 , wherein the immunogenic composition further comprises an immunostimulating adjuvant.
4 . A method of stimulating immune activity against a tumor-associated self-antigen, HER2, in a subject, comprising: administering a nucleic acid encoding a protein consisting of: amino acid sequence SEO ID NO:2, the nucleic acid encoding the protein operably linked to a heterologous regulatory nucleic acid sequence.
5 . The method of claim 4 , wherein the nucleic acid is present in an expression vector.
6 . The method of claim 5 , wherein the expression vector is a virus.
7 . The method of claim 1 , wherein the immunogenic composition is characterized by one or more of: 1) effectiveness to stimulate immune activity against a specified tumor-associated self-antigen in a subject, 2) effectiveness to overcome self-tolerance of the specified tumor-associated self-antigen, and 3) substantial similarity to the native three dimensional structure of the specified tumor-associated self-antigen.